Inhibition of the cardiac fibroblast-enriched lncRNA Meg3 prevents cardiac fibrosis and diastolic dysfunction

Circulation Research

Volumn 121, Issue 5, 2017, Pages 575-583

  Piccoli, Maria Teresa ^a   Gupta, Shashi Kumar ^a   Viereck, Janika ^a   Foinquinos, Ariana ^a   Samolovac, Sabine ^a   Kramer, Freya Luise ^a   Garg, Ankita ^a   Remke, Janet ^a   Zimmer, Karina ^a   Batkai, Sandor ^a   Thum, Thomas ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Cardiac remodeling; Diastolic dysfunction; Fibroblasts; Matrix metalloproteinases; Noncoding RNA

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; GELATINASE A; LONG UNTRANSLATED RNA; MATERNALLY EXPRESSED GENE 3; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; MEG3 NON-CODING RNA, MOUSE; MMP2 PROTEIN, MOUSE;

ADULT; AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BIOINFORMATICS; CARDIAC MUSCLE CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOWN REGULATION; ENZYME ACTIVITY; GENE IDENTIFICATION; GENE ONTOLOGY; HEART FIBROBLAST; HEART HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; TISSUE LEVEL; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CARDIOMYOPATHY; CELL CULTURE; DIASTOLIC HEART FAILURE; FIBROBLAST; FIBROSIS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOMYOPATHIES; CELLS, CULTURED; FIBROBLASTS; FIBROSIS; HEART FAILURE, DIASTOLIC; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; RATS; RNA, LONG NONCODING; VENTRICULAR REMODELING;

EID: 85021139247     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.310624     Document Type: Article

References (25)

1. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87:1285-1342. doi:10.1152/physrev.00012.2007.
2. Viereck J, Kumarswamy R, Foinquinos A, et al. Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med. 2016;8:326ra22. doi:10.1126/scitranslmed.aaf1475.
3. Tao H, Cao W, Yang JJ, Shi KH, Zhou X, Liu LP, Li J. Long noncoding RNA H19 controls DUSP5/ERK1/2 axis in cardiac fibroblast proliferation and fibrosis. Cardiovasc Pathol. 2016;25:381-389. doi:10.1016/j.carpath.2016.05.005.
4. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J Jr, Chien KR. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991;88:8277-8281.
5. Mondal T, Subhash S, Vaid R, et al. MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA-DNA triplex structures.Nat Commun. 2015;6:7743. doi:10.1038/ncomms8743.
6. Karagiannis ED, Popel AS. A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1 MMP in the presence of tissue inhibitor of metalloproteinase 2. J Biol Chem.2004;279:39105-39114.
7. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol. 1997;17:6330-6338.
8. Zhu J, Liu S, Ye F, Shen Y, Tie Y, Zhu J, Wei L, Jin Y, Fu H, Wu Y, Zheng X. Long noncoding RNA MEG3 interacts with p53 protein and regulates partial p53 target genes in hepatoma cells. PLoS One. 2015;10:e0139790.doi:10.1371/journal.pone.0139790.
9. Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C, Vacek JC, Abe OA, Tyagi SC. MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem. 2010;116:63-72. doi:10.3109/13813451003652997.
10. Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K, Kinugawa S, Tsutsui H. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension. 2006;47:711-717. doi:10.1161/01.HYP.0000208840.30778.00.
11. Miyoshi N, Wagatsuma H, Wakana S, Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino T, Ishino F. Identification of an imprinted gene, Meg3/Gtl2 and its human homologue MEG3, first mapped on mouse distal chromosome 12 and human chromosome 14q. Genes Cells. 2000;5:211-220.
12. Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor.J Mol Endocrinol. 2012;48:R45-R53. doi:10.1530/JME-12-0008.
13. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Klibanski A. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab. 2003;88:5119-5126.doi:10.1210/jc.2003-030222.
14. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab. 2005;90:2179-2186.doi:10.1210/jc.2004-1848.
15. He Y, Wu YT, Huang C, Meng XM, Ma TT, Wu BM, Xu FY, Zhang L, Lv XW, Li J. Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochim Biophys Acta.2014;1842:2204-2215. doi:10.1016/j.bbadis.2014.08.015.
16. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Ansell PJ, Zhao J, Weng C, Klibanski A. Activation of p53 by MEG3 non-coding RNA. J Biol Chem. 2007;282:24731-24742. doi:10.1074/jbc.M702029200.
17. Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y, Klibanski A. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology.2010;151:939-947. doi:10.1210/en.2009-0657.
18. Terashima M, Tange S, Ishimura A, Suzuki T. MEG3 long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines. J Biol Chem. 2017;292:82-99. doi:10.1074/jbc.M116.750950.
19. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction.Am J Physiol Heart Circ Physiol. 2007;292:H1847-H1860. doi:10.1152/ajpheart.00434.2006.
20. Yu H, Zhao G, Li H, Liu X, Wang S. Candesartan antagonizes pressure overload-evoked cardiac remodeling through Smad7 gene-dependent MMP-9 suppression. Gene. 2012;497:301-306. doi:10.1016/j.gene.2012.01.081.
21. Qiu GZ, Tian W, Fu HT, Li CP, Liu B. Long noncoding RNA-MEG3 is involved in diabetes mellitus-related microvascular dysfunction.Biochem Biophys Res Commun. 2016;471:135-141. doi:10.1016/j.bbrc.2016.01.164.
22. Boon RA, Hofmann P, Michalik KM, Lozano-Vidal N, Berghäuser D, Fischer A, Knau A, Jaé N, Schürmann C, Dimmeler S. Long noncoding RNA Meg3 controls endothelial cell aging and function: implications for regenerative angiogenesis. J Am Coll Cardiol. 2016;68:2589-2591. doi:10.1016/j.jacc.2016.09.949.
23. Gordon FE, Nutt CL, Cheunsuchon P, Nakayama Y, Provencher KA, Rice KA, Zhou Y, Zhang X, Klibanski A. Increased expression of angiogenic genes in the brains of mouse meg3-null embryos. Endocrinology.2010;151:2443-2452. doi:10.1210/en.2009-1151.
24. Liu J, Li Q, Zhang KS, Hu B, Niu X, Zhou SM, Li SG, Luo YP, Wang Y, Deng ZF. Downregulation of the long non-coding RNA Meg3 promotes angiogenesis after ischemic brain injury by activating notch signaling. Mol Neurobiol. 2016. doi:10.1007/s12035-016-0270-z.
25. Dimmeler S, Ylä-Herttuala S. 14q32 miRNA cluster takes center stage in neovascularization. Circ Res. 2014;115:680-682. doi:10.1161/CIRCRESAHA.114.304973.